Idelalisib Interactions
There are 897 drugs known to interact with idelalisib, along with 7 disease interactions, and 1 alcohol/food interaction. Of the total drug interactions, 233 are major, 646 are moderate, and 18 are minor.
- View all 897 medications that may interact with idelalisib
- View idelalisib alcohol/food interactions (1)
- View idelalisib disease interactions (7)
Most frequently checked interactions
View interaction reports for idelalisib and the medicines listed below.
- Adakveo (crizanlizumab)
- Align (bifidobacterium infantis)
- Alvesco (ciclesonide)
- Amitiza (lubiprostone)
- Aranesp (darbepoetin alfa)
- Aspirin Low Strength (aspirin)
- Augmentin (amoxicillin / clavulanate)
- Azithromycin Dose Pack (azithromycin)
- B-12 (cyanocobalamin)
- Bactrim (sulfamethoxazole / trimethoprim)
- Belsomra (suvorexant)
- Botox (onabotulinumtoxinA)
- Breo Ellipta (fluticasone / vilanterol)
- Caprelsa (vandetanib)
- Celebrex (celecoxib)
- Claritin (loratadine)
- Co-trimoxazole (sulfamethoxazole / trimethoprim)
- Contrave (bupropion / naltrexone)
- Dificid (fidaxomicin)
- Droxia (hydroxyurea)
- Endocet (acetaminophen / oxycodone)
- Engerix-B Pediatric (hepatitis b pediatric vaccine)
- Euthyrox (levothyroxine)
- Eutroxsig (levothyroxine)
- Evrysdi (risdiplam)
- Gazyva (obinutuzumab)
- Givlaari (givosiran)
- Hizentra (immune globulin subcutaneous)
- Metoprolol Tartrate (metoprolol)
- Vitamin D3 (cholecalciferol)
Idelalisib alcohol/food interactions
There is 1 alcohol/food interaction with idelalisib.
Idelalisib disease interactions
There are 7 disease interactions with idelalisib which include:
- colitis
- dermatologic toxicities
- hepatic impairment
- infections
- intestinal perforation
- neutropenia
- lung toxicity
Report options
More about idelalisib
- idelalisib consumer information
- Compare alternatives
- Reviews (2)
- Side effects
- Dosage information
- During pregnancy
- Drug class: PI3K inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Kesimpta
Kesimpta is used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated ...
Imbruvica
Imbruvica (ibrutinib) is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic ...
Calquence
Calquence (acalabrutinib) is used to treat chronic lymphocytic leukemia (CLL), and mantle cell ...
Brukinsa
Brukinsa is used to treat adults with mantle cell lymphoma, Waldenström’s macroglobulinemia, ma ...
Venclexta
Venclexta may be used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma ...
Ibrutinib
Ibrutinib (Imbruvica) is a Bruton's tyrosine kinase inhibitor used for certain blood cancers and ...
Venetoclax
Venetoclax (brand name Venclexta) may be used to treat CLL, SLL, or AML in those aged 75 years or ...
Cyclophosphamide
Cyclophosphamide is used for acute lymphocytic leukemia, acute nonlymphocytic leukemia, brain ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
